title: Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.
abstract: While the NGcGM3/VSSP vaccine, a preparation consisting in very small sized proteoliposomes (VSSP) obtained by the incorporation of the NGcGM3 ganglioside into the outer membrane protein (OMP) complex of Neisseria meningitides, is currently studied in late stage clinical trials in breast cancer and melanoma patients, mechanisms involved in the vaccine's antitumor effect are insufficiently understood. Here we have addressed the role of adaptive and innate immune cells in mediating the protective effect of the vaccine. To this aim we selected the 3LL-D122 Lewis lung spontaneous metastasis model. Unexpectedly, inoculation of the vaccine in tumor bearing C57BL/6 mice, either by subcutaneous (sc) or intraperitoneal (ip) routes, induced similar anti-metastatic effect. Regardless the T-independent nature of NGcGM3 ganglioside as antigen, the antimetastatic effect of NGcGM3/VSSP is dependent on CD4(+) T cells. In a further step we found that the vaccine was able to promote the increase, maturation, and cytokine secretion of conventional DCs and the maturation of Bone Marrow-derived plasmacytoid DCs. In line with this result the in vivo IFNα serum level in ip vaccinated mice increased as soon as 2h after treatment. On the other hand the infiltration of NK1.1(+)CD3(-) and NK1.1(+)CD3(+) cells in lungs of vaccinated mice was significantly increased, compared with the presence of these cells in control animal lungs. In the same way NGcGM3/VSSP mobilized acquired immunity effector cells into the lungs of vaccinated tumor bearing mice. Finally and not less noteworthy, leukocyte infiltration in lungs of tumor bearing mice correlates with vaccine induced inhibition of lung metastization.
authors.affiliation: a Center of Molecular Immunology (CIM); Immunobiology Division; Atabey; Havana Cuba.
authors.forename: Mayrel
authors.initials: M
authors.lastname: Labrada
authors.forename: Isabel
authors.initials: I
authors.lastname: Pablos
authors.forename: Francesca
authors.initials: F
authors.lastname: Prete
authors.forename: Giselle
authors.initials: G
authors.lastname: Hevia
authors.forename: Marilyn
authors.initials: M
authors.lastname: Clavell
authors.forename: Federica
authors.initials: F
authors.lastname: Benvenuti
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fernández
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002465:Cell Movement; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000097:blood; D007962:Leukocytes / Q000276:immunology*; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D016898:Interferon-alpha
keywords: NGcGM3; VSSP; cancer immunotherapy; ganglioside; leukocyte infiltration